

IFW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 3, 2006

Signature

Katherine L. Neville
(Katherine L. Neville)

Docket No.: 28967/39670A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/573,135

Confirmation No.: Not Yet Assigned

Filed: March 23, 2006

Art Unit: Not Yet Assigned

For: VEGF-C OR VEGF-D MATERIALS AND
METHODS FOR STIMULATION OF
NEURAL STEM CELLS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §1.56, 1.97 and §1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR §1.97(b)(3)).

In accordance with 37 CFR §1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR §1.98(a)(2).

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. In accordance with 37 CFR


§1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28967/39670A. A copy of this paper is enclosed.

Dated: January 3, 2006

Respectfully submitted,

By 

Katherine L. Neville

Registration No.: 53,379

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,135
				Filing Date	March 23, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	Not Yet Assigned
				Examiner Name	
Sheet	1	of	6	Attorney Docket Number	28967/39670A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-5,196,315	03-23-1993	Ronnett et al.	
	A2	US-5,585,089	12-17-1996	Queen et al.	
	A3	US-5,607,918	03-04-1997	Eriksson et al.	
	A4	US-5,643,759	07-01-1997	Pfreundschuh et al.	
	A5	US-5,654,183	08-05-1997	Anderson et al.	
	A6	US-5,693,762	12-02-1997	Queen et al.	
	A7	US-5,776,755	07-07-1998	Alitalo et al.	
	A8	US-5,798,229	08-25-1998	Strittmatter et al.	
	A9	US-5,840,693	11-24-1998	Eriksson et al.	
	A10	US-5,932,540	08-03-1999	Hu et al.	
	A11	US-5,935,820	08-10-1999	Hu et al.	
	A12	US-5,952,199	09-14-1999	Davis-Smyth	
	A13	US-6,040,157	03-21-2000	Hu et al.	
	A14	US-6,100,071	08-08-2000	Davis-Smyth	
	A15	US-6,107,046	08-22-2000	Alitalo et al.	
	A16	US-6,130,071	10-10-2000	Alitalo et al.	
	A17	US-6,221,839	04-24-2001	Alitalo et al.	
	A18	US-6,235,713	05-22-2001	Achen et al.	
	A19	US-6,245,530	06-12-2001	Alitalo et al.	
	A20	US-6,245,965	06-12-2001	Roussel et al.	
	A21	US-6,331,302	12-18-2001	Bennett	
	A22	US-6,361,946	03-26-2002	Alitalo et al.	
	A23	US-6,383,484	05-07-2002	Achen et al.	
	A24	US-6,383,486	05-07-2002	Davis-Smyth	
	A25	US-6,403,088	06-11-2002	Alitalo	
	A26	US-6,451,764	09-17-2002	Lee et al.	
	A27	US-6,576,608	06-10-2003	Lee et al.	
	A28	US-6,608,182	08-19-2003	Rosen et al.	
	A29	US-6,645,933	11-11-2003	Alitalo et al.	
	A30	US-6,673,343	01-06-2004	Bennett et al.	
	A31	US-6,689,580	02-10-2004	Achen et al.	
	A32	US-6,730,658	05-04-2004	Alitalo et al.	
	A33	US-2001/0038842	11-08-2001	Achen et al.	
	A34	US-2002/0045261-A1	04-18-2002	Snyder et al.	
	A35	US-2002/0065218	05-30-2002	Achen et al.	
	A36	US-2002/0102260	08-01-2002	Achen et al.	
	A37	US-2002/0120123	08-29-2002	Rosen et al.	
	A38	US-2002/012481	09-05-2002	Oliviero	
	A39	US-2002/0127222	09-12-2002	Achen et al.	
	A40	US-2002/0146420	10-10-2002	Bennett et al.	
	A41	US-2002/0151489	10-17-2002	Gavereauz et al.	
	A42	US-2002/0182683	12-05-2002	Hu et al.	
	A43	US-2002/0197691	12-26-2002	Sugiyama	
	A44	US-2003/0008257	01-09-2003	Hu et al.	
	A45	US-2003/0028007	02-06-2003	Hu et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,135
				Filing Date	March 23, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	Not Yet Assigned
				Examiner Name	
Sheet	2	of	6	Attorney Docket Number	28967/39670A

	A46	US-2003/0040023-A1	02-27-2003	Klassen et al.	
	A47	US-2003/0091567	05-15-2003	Alitalo et al.	
	A48	US-2003/0092604	05-15-2003	Alitalo et al.	
	A49	US-2003/0125537	07-03-2003	Achen et al.	
	A50	US-2003/0166523	09-04-2003	Achen et al.	
	A51	US-2003/0166547	09-04-2003	Oliviero	
	A52	US-2003/0166873	09-04-2003	Lee et al.	
	A53	US-2003/0170786	09-11-2003	Rosen et al.	
	A54	US-2003/0175274	09-18-2003	Rosen et al.	
	A55	US-2003/0176674	09-18-2003	Rosen et al.	
	A56	US-2003/0180294	09-25-2003	DeVries	
	A57	US-2003/0211101	11-13-2003	Wise et al.	
	A58	US-2003/0211988	11-13-2003	Epstein	
	A59	US-2003/0215921	11-20-2003	Coleman	
	A60	US-2003/0228283	12-11-2003	Heinzerling et al.	
	A61	US-2003/0232437	12-18-2003	Zhang et al.	
	A62	US-2004/0037820	02-26-2004	Alitalo et al.	
	A63	US-2005/0032697	02/10/2005	Alitalo et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP-0935001	08-11-1999	Chugai Res Inst Molecular Med		
	B2	WO-92/01047	01-23-1992	Cambridge Antibody Technology Limited		
	B3	WO-96/26736	09-06-1996	Ludwig Institute for Cancer Research		
	B4	WO-97/12972	04-10-1997	University of Siena		
	B5	WO-98/02543	01-22-1998	Chugai Res Inst Molecular Med		
	B6	WO-98/07832	02-26-1998	Ludwig Institute for Cancer Research		
	B7	WO-98/33917	08-06-1998	Ludwig Institute for Cancer Research		
	B8	WO-99/25869	05-27-1999	Pharma-Zentrale GMBH		
	B9	WO-00/21560	04-20-2000	Ludwig Institute for Cancer Research		
	B10	WO-00/45835	08-10-2000	Human Genome Sciences Inc		
	B11	WO-04/009773	01-29-2004	Ludwig Institute for Cancer Research		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,135
				Filing Date	March 23, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	Not Yet Assigned
				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	28967/39670A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	Aboody-Guterman et al., <i>NeuroReport</i> , Vol. 8, pp.3801-3808 (1997).		
	C2	Achen et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 95, pp.548-553 (1998).		
	C3	Bambakidis et al., <i>J. Neurosurg.</i> , Vol. 99, pp.70-75 (2003).		
	C4	Banerjee et al., <i>Neurobiol. Dis.</i> , Vol. 7, pp.666-672 (2000).		
	C5	Bansal et al., <i>Dev. Neurosci.</i> , Vol. 25, pp.83-95 (2003).		
	C6	Begolka et al., <i>J. Immunol.</i> , Vol. 161, pp.4437-4446 (1998).		
	C7	Bellomo et al., <i>Circ. Res.</i> , Vol. 86, E29-E35 (2000).		
	C8	Bernardi et al., <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 167, pp.141-149 (2003).		
	C9	Bjorklund et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 99, pp.2344-2349 (2002).		
	C10	Breiteneder-Geleff et al., <i>Am. J. Pathol.</i> , Vol. 154, pp.385-394 (1999).		
	C11	Brown et al., <i>Genome Res.</i> , Vol. 12, pp.868-884 (2002).		
	C12	Brummelkamp et al., <i>Science</i> , Vol. 296, pp.550-553 (2002).		
	C13	Carter et al., <i>J. Hematotherapy</i> , Vol. 4, pp.463-470 (1995).		
	C14	Charnock-Jones, <i>Biol. Reprod.</i> , Vol. 51, pp.524-530 (1994).		
	C15	Chen et al., <i>Neuron</i> , Vol. 19, pp.547-559 (1997).		
	C16	Chen et al., <i>Neuron</i> , Vol. 25, pp.43-56 (2000).		
	C17	Cohen et al., <i>Biochem. Biophys. Res. Comm.</i> , Vol. 284, pp.395-403 (2001).		
	C18	Craig et al., <i>J. Neurosci.</i> , Vol. 16, pp.2649-2658 (1996).		
	C19	Crocker et al., <i>J. Neurosci.</i> , Vol. 23, pp.4081-4091 (2003).		
	C20	Dal Canto et al., <i>Mult Scler.</i> , Vol. 1, pp.95-103 (1995).		
	C21	De Vries et al., <i>Science</i> , Vol. 255, pp.989-991 (1992).		
	C22	Dumont et al., <i>Science</i> , Vol. 282, pp.946-949 (1998).		
	C23	Enholm et al., <i>Circ. Res.</i> , Vol. 88, pp.623-629 (2001).		
	C24	Facchiano et al., <i>J. Neurosurg.</i> , Vol. 97, pp.161-168 (2002).		
	C25	Ferrara, <i>J. Mol. Med.</i> , Vol. 77, pp.527-543 (1999).		
	C26	Fire et al., <i>Nature</i> , Vol. 391, pp.806-811 (1998).		
	C27	Frisen et al., <i>CMLS Cell. Mol. Life Sci.</i> , Vol. 54, pp.935-945 (1998).		
	C28	Fujisawa et al., <i>Cell Tissue Res.</i> , Vol. 290, pp.465-470 (1997).		
	C29	Fujisawa et al., <i>Current Opinion in Neurobiology</i> , Vol. 8, pp.587-592 (1998).		
	C30	Gage et al., <i>Ann. Rev. Neurosci.</i> , Vol. 18, pp.159-192 (1995).		
	C31	Gage et al., "Research & Perspectives in Neurosciences: Isolation, Characterization, & Utilization of CNS Stem Cells, Springer-Verlag, Heidelberg," (1997).		
	C32	Gage et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 92, pp.11879-11883 (1995).		
	C33	Gagnon et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 97, pp.2573-2578 (2000).		
	C34	Giger et al., <i>Neuron</i> , Vol. 21, pp.1079-1092 (1998).		
	C35	Giger et al., <i>Neuron</i> , Vol. 25, pp.29-41 (2000).		
	C36	Gluzman-Poltorak et al., <i>J. Biol. Chem.</i> , Vol. 275, pp.18040-18045 (2000).		
	C37	Gorio et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 99, pp.9450-9455 (2002).		
	C38	Hartman et al., <i>J. Neurosci.</i> , Vol. 22, pp.10083-10087 (2002).		
	C39	Hauser et al., <i>Growth Factors</i> , Vol. 9, pp.259-268 (1993).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,135
				Filing Date	March 23, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	Not Yet Assigned
				Examiner Name	
Sheet	4	of	6	Attorney Docket Number	28967/39670A

C40	He et al., <i>Cell</i> , Vol. 90, pp.739-751 (1997).	
C41	Hickey et al., <i>Prog. Neuropsychopharmacol Biol. Psychiatry</i> , Vol. 27, pp.255-265 (2003).	
C42	Hirsch et al., <i>Brain Res.</i> , Vol. 823, pp.67-79 (1999).	
C43	Ishida et al., <i>J. Cell. Physiol.</i> , Vol. 188, pp.359-368 (2001).	
C44	Jander et al., <i>J. Neuroimmunol.</i> , Vol. 114, pp.253-258 (2001).	
C45	Jeltsch et al., <i>Science</i> , Vol. 276, pp.1423-1425 (1997).	
C46	Jiang et al., <i>J. Neurobiol.</i> , Vol. 44, pp.7-19 (2000).	
C47	Jones et al., <i>Nature</i> , Vol. 321, pp.522-525 (1986).	
C48	Joukov et al., <i>EMBO J.</i> , Vol. 15, pp.290-298 (1996).	
C49	Joukov et al., <i>EMBO J.</i> , Vol. 16, No. 13, pp.3898-3911 (1997).	
C50	Joukov et al., <i>J. Cell. Physiol.</i> , Vol. 173, pp.211-215 (1997).	
C51	Jussila et al., <i>Cancer Res.</i> , Vol. 58, pp.1599-1604 (1998).	
C52	Kaipainen et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 92, pp.3566-3570 (1995).	
C53	Karkkainen et al., <i>Nat. Genet.</i> , Vol. 25, pp.153-159 (2000).	
C54	Kaushal et al., <i>Nat. Med.</i> , Vol. 7, pp.1035-1040 (2001).	
C55	Kawasaki et al., <i>Development</i> , Vol. 126, pp.4895-4902 (1999).	
C56	Kitsukawa et al., <i>Development</i> , Vol. 121, pp.4309-4318 (1995).	
C57	Kolodkin et al., <i>Cell</i> , Vol. 90, pp.753-762 (1997).	
C58	Konobu et al., <i>Cell Transplant</i> , Vol. 7, pp.549-558 (1998).	
C59	Korpelainen et al., <i>J. Cell. Biol.</i> , Vol. 143, pp.1705-1721 (1998).	
C60	Kortt et al., <i>Biomol. Eng.</i> , Vol. 18, pp.95-108 (2001).	
C61	Krassioukov et al., <i>Am. J. Physiol.</i> , Vol. 268, pp.H2077-H2083 (1995).	
C62	Kuk et al., <i>Development</i> , Vol. 122, pp.3829-3837 (1996).	
C63	Kurreck et al., <i>Nucleic Acid Res.</i> , Vol. 30, pp.1911-1918 (2002).	
C64	Lacoraza et al., <i>Nature Med.</i> , Vol. 2, pp.424-429 (1996).	
C65	Laitinen et al., <i>Hum. Gene Ther.</i> , Vol. 9, pp.1481-1486 (1998).	
C66	Lamarre-Cliche et al., <i>Can J Clin Pharmacol.</i> , Vol. 6, pp.213-215 (1999).	
C67	Lee et al., <i>Nat. Biotechnol.</i> , Vol. 19, pp.500-505 (2002).	
C68	Lima et al., <i>J. Biol. Chem.</i> , Vol. 272, pp.626-638 (1997).	
C69	Luttun et al., <i>Ann NY Acad Sci.</i> , Vol. 979, pp.80-93 (2002).	
C70	Maglione et al., <i>Oncogene</i> , Vol. 8, pp.925-931 (1993).	
C71	Mak et al., <i>J. Clin. Neurosci.</i> , Vol. 7, pp.452 (2000).	
C72	Makinen et al., <i>J. Biol. Chem.</i> , Vol. 274, pp.21217-21222 (1999).	
C73	Makinen et al., <i>Nat. Med.</i> , Vol. 7, pp.199-205 (2001).	
C74	Matsushima et al., <i>Brain Pathol.</i> , Vol. 11, pp.107-116 (2001).	
C75	Matthews et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 88, pp.9026-9030 (1991).	
C76	Meyer et al., <i>EMBO J.</i> , Vol. 18, pp.363-374 (1999).	
C77	Miao et al., <i>FASEB J.</i> , Vol. 14, pp.2532-2539 (2000).	
C78	Migdal et al., <i>J. Biol. Chem.</i> , Vol. 273, pp.22272-22278 (1998).	
C79	Morrison et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 81, pp.6851-6855 (1984).	
C80	Muller et al., <i>Structure</i> , Vol. 5, pp.1325-1338 (1997).	
C81	Nakatomi et al., <i>Cell</i> , Vol. 110, pp.429-441 (2002).	
C82	Neuberger et al., <i>Nature</i> , Vol. 312, pp.604-608 (1984).	
C83	Neufeld et al., <i>FASEB J.</i> , Vol. 13, pp.9-22 (1999).	
C84	Oliver et al., <i>Mech Dev.</i> , Vol. 44, pp.3-16 (1993).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,135
				Filing Date	March 23, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	Not Yet Assigned
				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	28967/39670A

C85	Olofsson et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 93, pp.2576-2581 (1996).	
C86	Olson, <i>Exp. Neurol.</i> , Vol. 124, pp.5-15 (1993).	
C87	Ono et al., <i>Neuron</i> , Vol. 19, pp.283-292 (1997).	
C88	Ortega et al., <i>Fron. Biosci.</i> , Vol. 4, pp.141-152 (1999).	
C89	Owens et al., <i>J. Immunol. Meth.</i> , Vol. 168, pp.149-165 (1994).	
C90	Pajusola et al., <i>Oncogene</i> , Vol. 9, pp.3545-3555 (1994).	
C91	Park, J. <i>Neurotrauma</i> , Vol. 16, pp.675-687 (1999).	
C92	Partanen et al., <i>FASEB J.</i> , Vol. 14, pp.2087-2096 (2000).	
C93	Pasterkamp et al., <i>Brain Res. Rev.</i> , Vol. 35, pp.36-54 (2000).	
C94	Patel et al., <i>Optometry</i> , Vol. 74, pp.245-256 (2003).	
C95	Pavelock et al., <i>Endocrinology</i> , Vol. 142, pp.613-622 (2001).	
C96	Penkowa et al., <i>J. Neurosci Res.</i> , Vol. 72, pp.574-586 (2003).	
C97	Petrova et al., <i>Exp. Cell. Res.</i> , Vol. 253, pp.117-130 (1999).	
C98	Picard-Riera et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 99, pp.13211-13216 (2002).	
C99	Pluckthun et al., <i>Immunotechnology</i> , Vol. 3, pp.83-105 (1997).	
C100	Prevo et al., <i>J. Biol. Chem.</i> , Vol. 276, pp.19420-19430 (2001).	
C101	Puumalainen et al., <i>Hum. Gene Ther.</i> , Vol. 9, pp.1769-1774 (1998).	
C102	Quinn et al., <i>J. Neuroimmunol.</i> , Vol. 137, pp.32-41 (2003).	
C103	Renner et al., <i>Immunological Reviews</i> , No. 145, pp.179-209 (1995).	
C104	Richardson et al., <i>Glia</i> , Vol. 29, pp.136-142 (2000).	
C105	Riechmann et al., <i>Nature</i> , Vol. 332, pp.323-327 (1988).	
C106	Riess et al., <i>Neurosurgery</i> , Vol. 51, pp.1043-1052 (2002).	
C107	Robinson et al., <i>J. Cell Science</i> , Vol. 114, pp.853-865 (2001).	
C108	Ronnett et al., <i>Science</i> , Vol. 248, pp.603-605 (1990).	
C109	Rossignol et al., <i>Genomics</i> , Vol. 70, pp.211-222 (2000).	
C110	Rossignol et al., <i>Genomics</i> , Vol. 57, pp.459-460 (1999).	
C111	Rowitch et al., <i>Trends in Neurosci.</i> , Vol. 25, pp.417-422 (2002).	
C112	Salven et al., <i>Blood</i> , Vol. 101, No. 1, pp.168-172 (2003).	
C113	Schmid et al., <i>J. Neurosci.</i> , Vol. 20, pp.729-735 (2000).	
C114	Snyder et al., <i>Cell</i> , Vol. 68, pp.33-51 (1992).	
C115	Snyder et al., <i>Nature</i> , Vol. 374, pp.367-370 (1995).	
C116	Snyder, <i>The Neuroscientist</i> , Vol. 4, pp.408-425 (1998).	
C117	Soker et al., <i>Cell</i> , Vol. 92, pp.735-745 (1998).	
C118	Sondell et al., <i>J. Neurosci.</i> , Vol. 19, pp.5731-5740 (1999).	
C119	Spassky et al., <i>Development</i> , Vol. 128, pp.4993-5004 (2001).	
C120	Spassky et al., <i>Glia</i> , Vol. 29, pp.143-148 (2000).	
C121	Stacker et al., <i>Growth Factors</i> , Vol. 17, pp.1-11 (1999).	
C122	Tagaki et al., <i>Neuron</i> , Vol. 7, pp.295-307 (1991).	
C123	Taipale et al., <i>Curr. Top Microbiol. Immunol.</i> , Vol. 237, pp.85-96 (1999).	
C124	Takeda et al., <i>Nature</i> , Vol. 314, pp.452-454 (1985).	
C125	Tamagnone et al., <i>Trends in Cell Biol.</i> , Vol. 10, pp.377-383 (2000).	
C126	Temple, <i>Nature</i> , Vol. 414, pp.112-117 (2001).	
C127	Tepper et al., <i>Plastic and Reconstructive Surgery</i> , Vol. 111, pp.846-854 (2003).	
C128	Terman et al., <i>Biochem. Biophys. Res. Comm.</i> , Vol. 187, pp.1579-1586 (1992).	
C129	Thompson et al., <i>Am. J. Physiol. Heart Circ. Physiol.</i> , Vol. 281, pp.H396-H403 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,135
				Filing Date	March 23, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	Not Yet Assigned
				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	28967/39670A

C130	Todorovska et al., <i>J. Immunol Methods</i> , Vol. 248, pp.47-66 (2001).	
C131	Turner-Stokes, <i>Disabil. Rehabil.</i> , Vol. 24, pp.939-947 (2002).	
C132	Tuschl, <i>Nat. Biotechnol.</i> , Vol. 20, pp.446-448 (2002).	
C133	Veikkola et al., <i>EMBO J.</i> , Vol. 20, pp.1223-1231 (2001).	
C134	Verhoeven et al., <i>Science</i> , Vol. 239, pp.1534-1536 (1988).	
C135	Vicario-Abejon et al., <i>Neuron</i> , Vol. 15, pp.105-114 (1995).	
C136	Walkersville, Md., <i>Clonetics</i> , catalog number CC-2599.	
C137	Wang et al., <i>J. Neurosci.</i> , Vol. 14, pp.4446-4457 (1994).	
C138	Whitaker et al., <i>J. Bio. Chem.</i> , Vol. 276, pp.25520-25531 (2001).	
C139	Whittemore et al., <i>Mol. Neurobiology</i> , Vol. 12, pp.13-38 (1996).	
C140	Wigle et al., <i>Cell</i> , Vol. 98, pp.769-778 (1999).	
C141	Wigle et al., <i>EMBO J.</i> , Vol. 21, pp.1505-1513 (2002).	
C142	Yu et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 99, pp.6047-6052 (2002).	
C143	Yuan et al., <i>Development</i> , Vol. 129, pp.4797-4806 (2002).	
C144	Zachary, <i>Intl. J. Biochem. Cell. Bio.</i> , Vol. 30, pp.1169-1174 (1998).	
C145	Zou et al., <i>J. Neuroimmunol.</i> , Vol. 98, pp.168-175 (1999).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/92 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/573,135

Attorney Docket No.: 28967/39670A

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on January 3, 2006
Date

Signature

Katherine L. Neville

Typed or printed name of person signing Certificate

53,379
Registration Number, if applicable

(312) 474-6632
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (219 References) (6 pages)